Haw Par Corporation Limited (HAWPY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Haw Par Corporation Limited (HAWPY) trades at $54.44 with AI Score 50/100 (Grade B). Haw Par Corporation Limited is a Singapore-based conglomerate operating in healthcare, investments, property, and leisure. Market cap: $3.01B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for HAWPY: HAWPY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HAWPY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HAWPY: the 1 perspectives are evenly split.
How is this calculated? →Haw Par Corporation Limited (HAWPY) Healthcare & Pipeline Overview
Haw Par Corporation Limited is a Singaporean conglomerate with a diversified portfolio spanning healthcare products like Tiger Balm, strategic investments, commercial and industrial property leasing, and leisure operations including oceanariums. This multi-segment approach provides a unique market position, blending established consumer brands with asset-backed income streams across Singapore and international markets.
What Is the Investment Thesis for HAWPY?
Haw Par Corporation Limited presents a unique investment profile characterized by its diversified business model and established brand equity. With a market capitalization of $3.01B and a P/E ratio of 13.4, the company demonstrates a stable valuation. Its impressive Profit Margin of 115.4% and Gross Margin of 56.0% underscore strong operational efficiency and profitability across its segments. The Healthcare division, anchored by globally recognized brands like Tiger Balm and Kwan Loong, provides a resilient revenue base. This is complemented by a substantial property portfolio of 45,324 square meters, generating stable rental income, and an Investments segment actively managing quoted securities for capital appreciation. A low Beta of 0.18 suggests lower market volatility, while a 2.51% dividend yield offers income potential. This diversified approach, spanning consumer healthcare, real estate, and financial investments, aims to mitigate risks and provide consistent returns across various economic cycles.
Based on FMP financials and quantitative analysis
HAWPY Key Highlights
- Market Capitalization of $3.01B, reflecting its substantial presence as a diversified conglomerate.
- Impressive Profit Margin of 115.4%, indicating strong profitability relative to revenue.
- Robust Gross Margin of 56.0%, showcasing efficient cost management in its core operations.
- Low Beta of 0.18, suggesting lower volatility compared to the broader market, potentially appealing to conservative investors.
- Dividend Yield of 2.51%, providing income generation for shareholders.
Who Are HAWPY's Competitors?
HAWPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| CHJTF CSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.18B | 50 |
| BMYMP Bristol-Myers Squibb Company PFD CONV 2 | $400.00 | -57.46% | $814.59B | 50 |
| OGN Organon & Co. | $13.52 | -0.26% | $3.55B | 50 |
| BAYRY Bayer AG | $14.56 | -4.11% | $57.24B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HAWPY's Key Strengths?
- Established global brands (Tiger Balm, Kwan Loong) with strong consumer recognition.
- Diversified revenue streams across healthcare, property, investments, and leisure.
- Strong profitability metrics including a 115.4% Profit Margin and 56.0% Gross Margin.
- Significant asset base with 45,324 square meters of owned and leased investment properties.
What Are HAWPY's Weaknesses?
- Potential for slower growth in mature healthcare product markets compared to innovative biopharma.
- Reliance on regional tourism for the performance of its leisure segment.
- Exposure to real estate market fluctuations in Singapore and Malaysia.
- Limited public disclosure for its OTC trading status, potentially impacting investor confidence.
What Could Drive HAWPY Stock Higher?
- Expansion of Tiger Balm and Kwan Loong into new international markets, driving healthcare segment revenue growth through broader distribution and marketing efforts.
- Strategic optimization and potential acquisition of additional high-yield investment properties, enhancing rental income and asset value within the 'Others' segment.
- Recovery and sustained growth in global tourism, boosting performance of the leisure segment's oceanariums through increased visitor numbers and revenue.
- Prudent management of the investment portfolio, capitalizing on market opportunities for capital appreciation and dividend income from quoted securities.
- Introduction of new product variations or adjacent healthcare solutions under established brands to capture broader market segments and consumer needs.
What Are the Key Risks for HAWPY?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the US Dollar, impacting ADR holder returns and the company's reported financials.
- Geopolitical risks and economic instability in Southeast Asia, potentially affecting consumer spending, tourism, and property values in its key operating regions.
- Intense competition in the topical analgesic market from both established pharmaceutical companies and new entrants, potentially eroding market share or pricing power.
- Volatility in global equity markets affecting the performance and valuation of the Investments segment's quoted securities portfolio.
- Regulatory changes or increased scrutiny in the healthcare, property, or leisure sectors in its operating regions, potentially impacting operational costs or business models.
What Are the Growth Opportunities for HAWPY?
- **Global Expansion of Healthcare Brands**: Haw Par's established Tiger Balm and Kwan Loong brands possess significant international recognition. Expanding distribution networks and marketing efforts into untapped emerging markets, particularly in regions with growing middle classes and increasing demand for traditional remedies, could unlock substantial revenue growth. The global topical analgesics market is projected to grow, driven by an aging population and increasing prevalence of musculoskeletal conditions. Leveraging existing brand equity to introduce new product variations or adjacent healthcare solutions could further capture market share, with a timeline for this expansion being ongoing over the next 3-5 years.
- **Strategic Property Portfolio Enhancement**: The company owns and leases 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Opportunities exist to optimize this portfolio through strategic redevelopments, asset enhancement initiatives, or acquisitions of high-yield properties in key urban centers. Growing demand for logistics and industrial spaces, coupled with a recovering commercial real estate market in Southeast Asia, presents a clear path for increased rental income and capital appreciation over the medium term (3-7 years). This strategic management can significantly bolster the 'Others' segment's contribution.
- **Leisure Segment Development and Tourism Recovery**: Haw Par's leisure alternatives, primarily oceanariums, are poised for growth with the ongoing recovery and expansion of global tourism. Investing in new attractions, enhancing visitor experiences, or expanding into new leisure destinations, particularly within the growing Asian tourism market, could significantly boost this segment's contribution. As international travel normalizes and disposable incomes rise in the region, demand for family-oriented leisure activities is expected to increase over the next 2-5 years, providing a strong tailwind for this division.
- **Diversified Investment Portfolio Growth**: The Investments segment, which primarily invests in quoted securities, offers a flexible avenue for capital appreciation and income generation. Strategic allocation into high-growth sectors, emerging technologies, or dividend-yielding assets can enhance overall profitability. Opportunities include leveraging market volatility for tactical investments or forming strategic partnerships to gain exposure to new asset classes, contributing to overall corporate profitability on an ongoing basis, with potential for significant returns over a 5-10 year horizon, thereby strengthening the company's financial foundation.
- **Digital Transformation and E-commerce for Healthcare**: While a traditional brand, Tiger Balm can significantly benefit from enhanced digital marketing and e-commerce penetration. Investing in direct-to-consumer online channels, partnering with major e-retailers, and utilizing data analytics to understand consumer preferences can expand reach beyond traditional pharmacy shelves. This digital pivot could capture a younger demographic and increase market share in the rapidly growing online health and wellness sector, with implementation and scaling expected over the next 2-4 years, modernizing its distribution strategy.
What Opportunities Does HAWPY Have?
- Expansion into new international markets for healthcare products, leveraging existing brand equity.
- Optimization and potential acquisition of additional high-yield investment properties.
- Recovery and sustained growth in global tourism, boosting the leisure segment's performance.
- Strategic investments in high-growth sectors within its quoted securities portfolio.
What Threats Does HAWPY Face?
- Intense competition in the topical analgesic market from both established brands and new entrants.
- Currency exchange rate volatility, particularly between the Singapore Dollar and the US Dollar, affecting ADR holders.
- Geopolitical risks and economic downturns in Southeast Asia impacting consumer spending and property values.
- Regulatory changes or increased scrutiny in the healthcare or property sectors in its operating regions.
What Are HAWPY's Competitive Advantages?
- **Strong Brand Recognition**: Iconic brands like Tiger Balm and Kwan Loong have decades of global recognition and consumer trust, creating significant barriers to entry.
- **Diversified Business Model**: Multiple revenue streams from healthcare, property, investments, and leisure provide stability and reduce reliance on a single market or economic cycle.
- **Established Distribution Networks**: Extensive reach for healthcare products across Singapore, ASEAN, and international markets ensures broad market penetration.
- **Tangible Asset Base**: Ownership of significant commercial and industrial property assets provides a stable income stream and intrinsic value, acting as a hedge against market volatility.
- **Long Operating History**: Incorporated in 1969, demonstrating resilience, adaptability, and deep market experience over several decades.
What Does HAWPY Do?
Haw Par Corporation Limited, incorporated in Singapore in 1969, has evolved into a diversified conglomerate with operations spanning healthcare, investments, and property/leisure. Headquartered in Singapore, the company's core business is segmented into three principal areas: Healthcare, Investments, and Others. The Healthcare segment is primarily responsible for the manufacturing, marketing, and global distribution of its renowned topical analgesic products, notably the iconic Tiger Balm and Kwan Loong brands. These products have established a significant international presence, reaching consumers across Singapore, ASEAN countries, other Asian markets, and beyond. Beyond its well-known healthcare division, Haw Par Corporation maintains a substantial Investments segment, which focuses on strategic placements in quoted securities. This portfolio management contributes to the company's overall financial stability and growth. The 'Others' segment encompasses a diverse range of activities, including the ownership and leasing of a significant portfolio of investment properties. With a lettable area of 45,324 square meters, these commercial and industrial spaces in Singapore and Malaysia provide a consistent stream of rental income. Furthermore, this segment extends into the leisure industry, offering family and tourist-oriented attractions, principally in the form of oceanariums. The company also provides essential support services, such as leasing land, building, and office space, alongside offering management support services to its various subsidiaries and potentially external clients. This multi-faceted operational structure positions Haw Par Corporation Limited as a unique entity, blending traditional consumer healthcare with asset-backed income streams and leisure services.
What Products and Services Does HAWPY Offer?
- Manufactures and distributes topical analgesic products like Tiger Balm and Kwan Loong globally.
- Invests in quoted securities as part of its Investments segment.
- Owns and leases commercial and industrial investment properties in Singapore and Malaysia.
- Operates family and tourist-oriented leisure attractions, specifically oceanariums.
- Provides land, building, and office space leasing services.
- Offers management support services to its subsidiaries and potentially third parties.
How Does HAWPY Make Money?
- Generates revenue from the sale of healthcare products (topical analgesics) through its extensive distribution network.
- Earns income from rental fees through its portfolio of commercial and industrial investment properties.
- Derives returns from its investments in quoted securities, including dividends and capital gains.
- Collects revenue from ticket sales and related services at its leisure facilities (oceanariums).
- Receives income from leasing land, buildings, and office space, contributing to its 'Others' segment.
What Industry Does HAWPY Operate In?
Haw Par Corporation Limited operates within the 'Drug Manufacturers - General' industry, yet its business model significantly diverges from traditional pharmaceutical companies. While it manufactures and distributes well-known topical analgesics like Tiger Balm, its conglomerate structure extends into property and leisure, positioning it uniquely. The topical analgesic market, characterized by consumer-driven demand for over-the-counter pain relief, tends to be stable but competitive. Haw Par's established brand recognition provides a competitive edge in this segment. Its property and leisure operations, however, place it within the broader real estate and tourism sectors in Singapore and Malaysia, exposing it to different market dynamics and trends. This diversification allows Haw Par to potentially mitigate risks inherent in any single industry, contrasting with pure-play drug manufacturers that are often subject to patent cliffs and R&D cycles.
Who Are HAWPY's Key Customers?
- Consumers seeking topical pain relief solutions globally for its healthcare products.
- Businesses and individuals requiring commercial and industrial rental spaces in Singapore and Malaysia.
- Tourists and families visiting leisure attractions like oceanariums.
- Institutional and retail investors through its quoted securities investments.
- Subsidiaries and potentially external entities utilizing management support services.
How Haw Par Corporation Limited Is Valued
Haw Par Corporation Limited carries a market capitalization of $3.01B, placing it in the mid-cap category. Relative to its peer group, HAWPY's quantitative score of 50/100 is below the peer average of 60/100.
Company Profile
Haw Par Corporation Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Ee Lim Wee. HAWPY has traded publicly since 2013.
ROE 6%Key Financial Metrics
Return on equity for Haw Par Corporation Limited stands at 6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.0%, showing how much profit it generates from its asset base. HAWPY trades at a trailing price-to-earnings ratio of 13.37, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Haw Par Corporation Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 19.33 places it in the safe zone, indicating low near-term bankruptcy risk.
HAWPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established global brands (Tiger Balm, Kwan Loong) with strong consumer recognition.
- Diversified revenue streams across healthcare, property, investments, and leisure.
- Strong profitability metrics including a 115.4% Profit Margin and 56.0% Gross Margin.
- Significant asset base with 45,324 square meters of owned and leased investment properties.
Bear Case
- Potential for slower growth in mature healthcare product markets compared to innovative biopharma.
- Reliance on regional tourism for the performance of its leisure segment.
- Exposure to real estate market fluctuations in Singapore and Malaysia.
- Limited public disclosure for its OTC trading status, potentially impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HAWPY Latest News
No recent news available for HAWPY.
HAWPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HAWPY.
Price Targets
Wall Street price target analysis for HAWPY.
HAWPY MoonshotScore
What does this score mean?
The MoonshotScore rates HAWPY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ee Lim Wee
Chief Executive Officer
Unknown
Track Record: Unknown
Haw Par Corporation Limited ADR Information Unsponsored
HAWPY is an American Depositary Receipt (ADR) Level 1, representing shares of Haw Par Corporation Limited, which are primarily traded on the Singapore Exchange (HAWP). ADRs allow U.S. investors to buy shares of foreign companies without having to trade on foreign exchanges. As a Level 1 ADR, HAWPY trades on the U.S. over-the-counter (OTC) market, facilitating access for American investors to the company's equity.
- Home Market Ticker: Singapore Exchange (SGX), Singapore
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HAWP
HAWPY OTC Market Information
HAWPY trades on the OTC Other tier of the over-the-counter market. This tier is the lowest and most speculative of the OTC market segments, distinct from OTCQX Best Market and OTCQB Venture Market. Companies on the OTC Other tier are not required to meet minimum financial standards, nor do they typically provide comprehensive public disclosure to OTC Markets Group. This contrasts sharply with major exchanges like NYSE or NASDAQ, which have stringent listing requirements for market capitalization, share price, and financial reporting, aiming to ensure greater transparency and investor protection.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity and wider bid-ask spreads compared to exchange-listed stocks, impacting trade execution.
- Limited public disclosure, making comprehensive due diligence and access to financial information challenging.
- Increased volatility due to fewer market makers and less trading volume, potentially leading to significant price swings.
- Potential for less analyst coverage and institutional interest, which can affect market efficiency and price discovery.
- Greater susceptibility to market manipulation due to lower transparency and regulatory oversight compared to major exchanges.
- Verify the company's official filings with its home country regulator, such as the Singapore Exchange, for comprehensive financial data.
- Research the company's business operations, management team, and financial health thoroughly using all available information.
- Assess the historical trading volume and bid-ask spread to understand the stock's liquidity and potential trading costs.
- Understand the specific ADR structure, including the depositary bank, and associated currency risks between SGD and USD.
- Consult with a financial advisor experienced in OTC and international equities to navigate potential complexities.
- Evaluate the company's long-term strategic plans and its competitive position within its diversified business segments.
- Scrutinize any available financial statements for red flags, inconsistencies, or significant liabilities.
- Established operating history since 1969, indicating longevity and resilience in various economic cycles.
- Ownership of globally recognized and trusted brands like Tiger Balm and Kwan Loong.
- Diversified asset base including significant investment properties in Singapore and Malaysia.
- Traded as a Level 1 ADR, implying some level of oversight by a depositary bank and a legitimate underlying foreign entity.
- Headquartered in Singapore, a well-regulated financial jurisdiction with robust corporate governance standards.
Haw Par Corporation Limited Healthcare Stock: Key Questions Answered
What does Haw Par Corporation Limited do?
Haw Par Corporation Limited is a Singapore-based conglomerate with a multi-faceted business model. Its primary operations are divided into three segments: Healthcare, Investments, and Others. The Healthcare segment is renowned for manufacturing and distributing topical analgesic products under the globally recognized Tiger Balm and Kwan Loong brands. The Investments segment focuses on managing a portfolio of quoted securities. The 'Others' segment encompasses the ownership and leasing of commercial and industrial investment properties across Singapore and Malaysia, alongside operating family and tourist-oriented leisure attractions, specifically oceanariums. Additionally, it provides land, building, and office space leasing, and offers management support services.
How does Haw Par Corporation Limited's diversified business model contribute to its financial stability?
Haw Par Corporation Limited's diversified business model, spanning healthcare, investments, property, and leisure, is a key contributor to its financial stability. This multi-segment approach aims to mitigate risks associated with over-reliance on a single industry or market. For instance, strong performance in its established healthcare brands like Tiger Balm can offset potential downturns in the property market, or stable rental income from its real estate portfolio can provide a buffer during periods of equity market volatility affecting its investment segment. This blend of consumer-staple products, asset-backed income, and strategic investments provides varied income streams and enhances overall corporate resilience against economic fluctuations and sector-specific challenges, as reflected in its robust profit and gross margins.
What are the implications of Haw Par Corporation Limited trading as an ADR on the OTC market?
Trading as a Level 1 American Depositary Receipt (ADR) on the OTC Other market carries several implications for investors. Firstly, it provides U.S. investors access to a foreign company without direct international trading. However, the OTC Other tier is characterized by less stringent disclosure requirements compared to major exchanges, meaning investors may have access to less comprehensive or timely financial information. Secondly, OTC trading typically involves lower liquidity and wider bid-ask spreads, which can make it more challenging to buy or sell shares at desired prices and potentially lead to higher transaction costs. Lastly, ADR holders are exposed to currency risk, as the value of their investment and any dividends are subject to fluctuations between the Singapore Dollar and the U.S. Dollar.
What are the key factors to evaluate for HAWPY?
Haw Par Corporation Limited (HAWPY) holds an AI score of 50/100 (moderate). P/E: 13.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HAWPY data refresh on this page?
HAWPY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HAWPY's recent stock price performance?
Haw Par Corporation Limited (HAWPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global brands (Tiger Balm, Kwan Loong) with strong consumer recognition. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HAWPY overvalued or undervalued right now?
Haw Par Corporation Limited (HAWPY) trades at 13.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HAWPY?
Before investing in Haw Par Corporation Limited (HAWPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data as of 2026-06-15. No external research or speculative content has been included. Specific details for CEO background, tax implications for ADRs, and full OTC disclosure status were not provided and are marked as 'Unknown'.